ArticleFrontiers in endocrinology2026
Real-world identification of high-risk medications for drug-induced osteoporosis: a multi-method pharmacovigilance study based on FAERS with WHO Vigibase validation.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Using the FAERS database in conjunction with the WHO Vigibase, this study systematically evaluated the characteristics, high-risk drugs, and demographic factors associated with drug-induced osteoporosis, and analyzed the onset time patterns of adverse events for major implicated medications. Methods: Osteoporosis-related reports from FAERS between Q1-2014 and Q1-2025 were collected, and after deduplication, 55,895 cases were included. Disproportionality analyses (ROR, PRR, MGPS, BCPNN) and LASSO regression were applied to identify high-risk drugs. Multivariate regression was used to assess the independent effects of age, sex, and drug exposure. Onset time distribution analyses were conducted for the five drugs with the strongest signals, and external validation was performed using WHO Vigibase. Results: Reports of osteoporosis increased markedly after 2020, with females and individuals aged ≥60 years representing high-risk populations. Disproportionality analysis identified 18 associated drugs, with Tenofovir Disoproxil showing the highest number of reports and the strongest signal (ROR 367.06). LASSO regression further identified 17 strongly associated drugs, predominantly antineoplastic agents and immunosuppressants. Multivariate analysis indicated that age >60 years (OR = 3.7) and female sex (OR = 1.8) were significant risk factors, while Tenofovir Disoproxil (OR = 210) and Adefovir (OR = 59) exhibited the strongest drug-related risk signals. Onset time analysis revealed distinct temporal patterns among the five drugs: Tenofovir Disoproxil and Medroxyprogesterone had the highest cumulative risk and the broadest time distribution, whereas Adefovir and Anastrozole were mainly associated with early-onset events. External validation in WHO Vigibase corroborated the high-risk signals of Tenofovir Disoproxil and Adefovir. Conclusions: This comprehensive pharmacovigilance study identifies key medications associated with elevated osteoporosis risk and reveals marked differences in onset time patterns. These findings provide robust evidence to support targeted monitoring and inform individualized preventive strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.